AAAAAA

   
Results: 1-17 |
Results: 17
A COMPARISON OF EFFICACY OF SARGRAMOSTIM (YEAST-DERIVED RHUGM-CSF) AND FILGRASTIM (BACTERIA-DERIVED RHUG-CSF) IN THE THERAPEUTIC SETTING OFCHEMOTHERAPY-INDUCED MYELOSUPPRESSION
Authors: BEVERIDGE RA MILLER JA KALES AN BINDER RA ROBERT NJ HARVEY JH WINDSOR K GORE I CANTRELL J THOMPSON KA TAYLOR WR BARNES HM SCHIFF SA SHIELDS JA CAMBARERI RJ BUTLER TP MEISTER RJ FEIGERT JM NORGARD MJ MORAES MA HELVIE WW PATTON GA MUNDY LJ HENRY D MASON B STADDON A FORD P KATCHER D HOUCK W MAJOR WB GEMMA NW KAY G PRIEST E SOWROY P BANK B LEIBACH S REISEL H GRAD G WARREN RD UENO WM SMITH LF DOBRZYNSKI RF SHERIDAN MJ
Citation: Ra. Beveridge et al., A COMPARISON OF EFFICACY OF SARGRAMOSTIM (YEAST-DERIVED RHUGM-CSF) AND FILGRASTIM (BACTERIA-DERIVED RHUG-CSF) IN THE THERAPEUTIC SETTING OFCHEMOTHERAPY-INDUCED MYELOSUPPRESSION, Cancer investigation, 16(6), 1998, pp. 366-373
A MULTICENTER RANDOMIZED CLINICAL-TRIAL OF GOSERELIN VERSUS SURGICAL OVARIECTOMY IN PREMENOPAUSAL PATIENTS WITH RECEPTOR-POSITIVE METASTATIC BREAST-CANCER - AN INTERGROUP STUDY
Authors: TAYLOR CW GREEN S DALTON WS MARTINO S RECTOR D INGLE JN ROBERT NJ BUDD GT PARADELO JC NATALE RB BEARDEN JD MAILLIARD JA OSBORNE CK
Citation: Cw. Taylor et al., A MULTICENTER RANDOMIZED CLINICAL-TRIAL OF GOSERELIN VERSUS SURGICAL OVARIECTOMY IN PREMENOPAUSAL PATIENTS WITH RECEPTOR-POSITIVE METASTATIC BREAST-CANCER - AN INTERGROUP STUDY, Journal of clinical oncology, 16(3), 1998, pp. 994-999
RANDOMIZED TRIAL COMPARING THE TOLERABILITY OF SARGRAMOSTIM (YEAST-DERIVED RHUGM-CSF) AND FILGRASTIM (BACTERIA-DERIVED RHUG-CSF) IN CANCER-PATIENTS RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY
Authors: BEVERIDGE RA MILLER JA KALES AN BINDER RA ROBERT NJ HEISRATHEVANS J KOCZYKSCRIPKA K PASHKO S NORGARD MJ BARNES HM TAYLOR WR THOMPSON KA SMITH LF UENO WM DOBRZYNSKI RF WARREN RD KATCHER D BYRNE PJ DUNNING DM WINOKUR SH LOCKEY JL CAMBARERI RJ BUTLER TP MEISTER RJ FIEGERT JM
Citation: Ra. Beveridge et al., RANDOMIZED TRIAL COMPARING THE TOLERABILITY OF SARGRAMOSTIM (YEAST-DERIVED RHUGM-CSF) AND FILGRASTIM (BACTERIA-DERIVED RHUG-CSF) IN CANCER-PATIENTS RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY, Supportive care in cancer, 5(4), 1997, pp. 289-298
PHASE-II TRIAL OF BIWEEKLY PACLITAXEL AND CISPLATIN IN ADVANCED BREAST-CARCINOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY
Authors: SPARANO JA NEUBERG D GLICK JH ROBERT NJ GOLDSTEIN LJ SLEDGE GW WOOD W
Citation: Ja. Sparano et al., PHASE-II TRIAL OF BIWEEKLY PACLITAXEL AND CISPLATIN IN ADVANCED BREAST-CARCINOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY, Journal of clinical oncology, 15(5), 1997, pp. 1880-1884
RANDOMIZED PLACEBO-CONTROLLED STUDY OF RECOMBINANT HUMAN INTERLEUKIN-11 TO PREVENT CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA IN PATIENTS WITH BREAST-CANCER RECEIVING DOSE-INTENSIVE CYCLOPHOSPHAMIDE AND DOXORUBICIN
Authors: ISAACS C ROBERT NJ BAILEY FA SCHUSTER MW OVERMOYER B GRAHAM M CAI B BEACH KJ LOEWY JW KAYE JA
Citation: C. Isaacs et al., RANDOMIZED PLACEBO-CONTROLLED STUDY OF RECOMBINANT HUMAN INTERLEUKIN-11 TO PREVENT CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA IN PATIENTS WITH BREAST-CANCER RECEIVING DOSE-INTENSIVE CYCLOPHOSPHAMIDE AND DOXORUBICIN, Journal of clinical oncology, 15(11), 1997, pp. 3368-3377
ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - REPLY
Authors: COBLEIGH MA BERRIS RF BUSH T DAVIDSON NE ROBERT NJ SPARANO JA TORMEY DC WOOD WC
Citation: Ma. Cobleigh et al., ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - REPLY, JAMA, the journal of the American Medical Association, 273(8), 1995, pp. 621-621
ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - A TIME FOR CHANGE (VOL 272, PG 540, 1994)
Authors: COBLEIGH MA BERRIS RF BUSH T DAVIDSON NE ROBERT NJ SPARANO JA TORMEY DC WOOD WC
Citation: Ma. Cobleigh et al., ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - A TIME FOR CHANGE (VOL 272, PG 540, 1994), JAMA, the journal of the American Medical Association, 273(5), 1995, pp. 378-378
ADJUVANT THERAPY IN BREAST-CANCER
Authors: ROBERT NJ
Citation: Nj. Robert, ADJUVANT THERAPY IN BREAST-CANCER, Obstetrics and gynecology clinics of North America, 21(4), 1994, pp. 693-707
MANAGEMENT OF RECURRENT BREAST-CANCER
Authors: ROBERT NJ BEVERIDGE RA
Citation: Nj. Robert et Ra. Beveridge, MANAGEMENT OF RECURRENT BREAST-CANCER, Obstetrics and gynecology clinics of North America, 21(4), 1994, pp. 709-719
ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - A TIME FOR CHANGE
Authors: COBLEIGH MA BERRIS RF BUSH T DAVIDSON NE ROBERT NJ SPARANO JA TORMEY DC WOOD WC
Citation: Ma. Cobleigh et al., ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - A TIME FOR CHANGE, JAMA, the journal of the American Medical Association, 272(7), 1994, pp. 540-545
BREAST-CONSERVATION IN ELDERLY WOMEN FOR CLINICALLY NEGATIVE AXILLARYLYMPH-NODES WITHOUT AXILLARY DISSECTION
Authors: WAZER DE ERBAN JK ROBERT NJ SMITH TJ MARCHANT DJ SCHMID C DIPETRILLO T SCHMIDTULLRICH R
Citation: De. Wazer et al., BREAST-CONSERVATION IN ELDERLY WOMEN FOR CLINICALLY NEGATIVE AXILLARYLYMPH-NODES WITHOUT AXILLARY DISSECTION, Cancer, 74(3), 1994, pp. 878-883
FATTY-ACID COMPOSITION OF THE SUBCUTANEOUS ADIPOSE-TISSUE AND RISK OFPROLIFERATIVE BENIGN BREAST DISEASE AND BREAST-CANCER
Authors: LONDON SJ SACKS FM STAMPFER MJ HENDERSON IC MACLURE M TOMITA A WOOD WC REMINE S ROBERT NJ DMOCHOWSKI JR WILLETT WC
Citation: Sj. London et al., FATTY-ACID COMPOSITION OF THE SUBCUTANEOUS ADIPOSE-TISSUE AND RISK OFPROLIFERATIVE BENIGN BREAST DISEASE AND BREAST-CANCER, Journal of the National Cancer Institute, 85(10), 1993, pp. 785-793
PHASE-II STUDY OF GOSERELIN FOR PATIENTS WITH POSTMENOPAUSAL METASTATIC BREAST-CANCER
Authors: SAPHNER T TROXEL AB TORMEY DC NEUBERG D ROBERT NJ PANDYA KJ EDMONSON JH ROSENBLUTH RJ ABELOFF MD
Citation: T. Saphner et al., PHASE-II STUDY OF GOSERELIN FOR PATIENTS WITH POSTMENOPAUSAL METASTATIC BREAST-CANCER, Journal of clinical oncology, 11(8), 1993, pp. 1529-1535
AN ASSOCIATION BETWEEN THE RISK OF CANCER AND MUTATIONS IN THE HRAS1 MINISATELLITE LOCUS
Authors: KRONTIRIS TG DEVLIN B KARP DD ROBERT NJ RISCH N
Citation: Tg. Krontiris et al., AN ASSOCIATION BETWEEN THE RISK OF CANCER AND MUTATIONS IN THE HRAS1 MINISATELLITE LOCUS, The New England journal of medicine, 329(8), 1993, pp. 517-523
PHASE-I TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND 5-FLUOROURACIL PLUS INTERFERON-ALPHA-2B IN PATIENTS WITH ADVANCED BREAST-CANCER
Authors: SPARANO JA WADLER S LIEBES L ROBERT NJ SCHWARTZ EL DUTCHER JP
Citation: Ja. Sparano et al., PHASE-I TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND 5-FLUOROURACIL PLUS INTERFERON-ALPHA-2B IN PATIENTS WITH ADVANCED BREAST-CANCER, Cancer research, 53(15), 1993, pp. 3509-3512
COMPARISON OF TOXICITIES OF G-CSF AND YEAST-DERIVED GM-CSF
Authors: BEVERIDGE RA KALES AN BINDER RA ROBERT NJ MILLER JA
Citation: Ra. Beveridge et al., COMPARISON OF TOXICITIES OF G-CSF AND YEAST-DERIVED GM-CSF, Blood, 82(10), 1993, pp. 10000495-10000495
CANCER RISK AND THE HRAS1 MINISATELLITE LOCUS
Authors: KRONTIRIS TG DEVLIN B KARP DD ROBERT NJ RISCH N
Citation: Tg. Krontiris et al., CANCER RISK AND THE HRAS1 MINISATELLITE LOCUS, American journal of human genetics, 53(3), 1993, pp. 316-316
Risultati: 1-17 |